Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Nat Med. 2018 Sep 26;24(11):1701–1707. doi: 10.1038/s41591-018-0186-4

Figure 2. Viral load following 3BNC17/10–1074 infusions in HIV-1-infected participants.

Figure 2.

(a-c) Changes in viremia and bNAb serum concentrations in HIV-1-infected participants showing (a) late rebound, (b) early rebound or (c) no response after 3BNC117 and 10–1074 combination therapy. Upper graphs show HIV-1 RNA in copies/ml (black, left y-axis), and 3BNC117 (red) and 10–1074 (blue) serum levels (right y-axis, as determined by TZM-bl). X-axis shows weeks after the first antibody infusion. Dashed line indicates the lower limit of detection of HIV-1 RNA (20 copies/ml). Arrows indicate antibody infusions. Lower graphs show log10 changes of HIV-1 RNA copies compared to day 0. Green shading depicts viral suppression compared to day 0. (d-f) Simultaneous confidence band estimation to determine time of significant suppression (red dotted lines) of HIV-1 viremia in (d) all viremic participants (n=7, a-c), (e) individuals harboring 3BNC117- and 10–1074-sensitive viruses (n=4, a), and (f) participants carrying viruses with partial or full bNAb resistance (n=3, b-c). Each dot represents a viral load measurement. Solid and dashed lines represent the regression fit and simultaneous confidence bands at 95% certainty level, respectively, and were computed using the Gaussian family for the local likelihood function using R package locfit (version 1.5–9.1).